{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:31:09Z","timestamp":1792791069643,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Creative-Pioneering Researchers Program through Seoul National University","id":[{"id":"https:\/\/ror.org\/04h9pn542","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bio & Medical Technology Development Program of the National Research Foundation","award":["RS-2021-NR056559"],"award-info":[{"award-number":["RS-2021-NR056559"]}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"crossref","award":["RS-2024-00440679"],"award-info":[{"award-number":["RS-2024-00440679"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39406-6","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T02:05:15Z","timestamp":1770689115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimization of THP-1-CAR monocytes utilizing CD32a signaling phagocytosis for antigen-specific T cell activation"],"prefix":"10.1038","volume":"16","author":[{"given":"Jisu","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soojin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Kyung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Mu","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Rae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"39406_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan, K. et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J. Exp. Clin. Cancer Res. 41, 119 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"39406_CR2","doi-asserted-by":"publisher","first-page":"1675807","DOI":"10.3389\/fimmu.2025.1675807","volume":"16","author":"Y Hou","year":"2025","unstructured":"Hou, Y. et al. Beyond CAR-T cells: exploring CAR-NK, CAR-M, and CAR-\u03b3\u03b4 T strategies in solid tumor immunotherapy. Front. Immunol. 16, 1675807 (2025).","journal-title":"Front. Immunol."},{"key":"39406_CR3","doi-asserted-by":"publisher","first-page":"116066","DOI":"10.1016\/j.bcp.2024.116066","volume":"222","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Developing CAR-immune cell therapy against SARS-CoV-2: current status, challenges and prospects. Biochem. Pharmacol. 222, 116066 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"39406_CR4","doi-asserted-by":"publisher","first-page":"1613878","DOI":"10.3389\/fimmu.2025.1613878","volume":"16","author":"D Wu","year":"2025","unstructured":"Wu, D. et al. CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon. Front. Immunol. 16, 1613878 (2025).","journal-title":"Front. Immunol."},{"key":"39406_CR5","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/S0140-6736(25)01671-X","volume":"406","author":"J Gao","year":"2025","unstructured":"Gao, J. et al. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. Lancet 406, 2968\u20132979 (2025).","journal-title":"Lancet"},{"key":"39406_CR6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41551-025-01387-8","volume":"9","author":"Q Cao","year":"2025","unstructured":"Cao, Q. et al. Targeting inflammation with chimeric antigen receptor macrophages using a signal switch. Nat. Biomed. Eng. 9, 1502\u20131516 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"39406_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41571-025-01075-1","volume":"22","author":"J Li","year":"2025","unstructured":"Li, J., Liu, C., Zhang, P., Shen, L. & Qi, C. Optimizing CAR T cell therapy for solid tumours: a clinical perspective. Nat. Rev. Clin. Oncol. 22, 953\u2013968 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"39406_CR8","doi-asserted-by":"publisher","first-page":"1361194","DOI":"10.3389\/fimmu.2024.1361194","volume":"15","author":"T Li","year":"2024","unstructured":"Li, T. et al. CAR-NK cells for cancer immunotherapy: recent advances and future directions. Front. Immunol. 15, 1361194 (2024).","journal-title":"Front. Immunol."},{"key":"39406_CR9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","volume":"9","author":"M Alrehaili","year":"2025","unstructured":"Alrehaili, M., Couto, P. S., Khalife, R. & Rafiq, Q. A. CAR-macrophages in solid tumors: promise, progress, and prospects. Npj Precis Onc. 9, 382 (2025).","journal-title":"Npj Precis Onc"},{"key":"39406_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ejh.14076","volume":"112","author":"AN Khan","year":"2024","unstructured":"Khan, A. N., Asija, S., Pendhari, J. & Purwar, R. CAR-T cell therapy in hematological malignancies: where are we now and where are we heading for? Eur. J. Haematol. 112, 6\u201318 (2024).","journal-title":"Eur. J. Haematol."},{"key":"39406_CR11","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Zhu, L., Zhang, H., Chen, S. & Xiao, Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front. Immunol. 13, 927153 (2022).","journal-title":"Front. Immunol."},{"key":"39406_CR12","doi-asserted-by":"publisher","first-page":"123300","DOI":"10.1016\/j.lfs.2024.123300","volume":"361","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Exploring the potential of CAR-macrophage therapy. Life Sci. 361, 123300 (2025).","journal-title":"Life Sci."},{"key":"39406_CR13","doi-asserted-by":"crossref","unstructured":"Fu, W. et al. CAR macrophages for SARS-CoV-2 immunotherapy. Front Immunol 12, (2021).","DOI":"10.3389\/fimmu.2021.669103"},{"key":"39406_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102\u2013116 (2024).","journal-title":"Nat. Immunol."},{"key":"39406_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41423-024-01220-3","volume":"21","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Silencing of SIRP\u03b1 enhances the antitumor efficacy of CAR-M in solid tumors. Cell. Mol. Immunol. 21, 1335\u20131349 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"39406_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/imr.12212","volume":"262","author":"SA Freeman","year":"2014","unstructured":"Freeman, S. A. & Grinstein, S. Phagocytosis: receptors, signal integration, and the cytoskeleton. Immunol. Rev. 262, 193\u2013215 (2014).","journal-title":"Immunol. Rev."},{"key":"39406_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Macrophages in immunoregulation and therapeutics. Sig Transduct. Target. Ther. 8, 207 (2023).","journal-title":"Sig Transduct. Target. Ther."},{"key":"39406_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799\u2013820 (2022).","journal-title":"Nat. Rev. Drug Discov"},{"key":"39406_CR19","doi-asserted-by":"crossref","unstructured":"Muntjewerff, E. M. & Meesters, L. D. & van den Bogaart, G. Antigen Cross-Presentation by macrophages. Front Immunol 11, (2020).","DOI":"10.3389\/fimmu.2020.01276"},{"key":"39406_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"39406_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41421-024-00718-4","volume":"10","author":"Z Gao","year":"2024","unstructured":"Gao, Z. et al. Targeting cardiac fibrosis with chimeric antigen receptor macrophages. Cell. Discov. 10, 86 (2024).","journal-title":"Cell. Discov"},{"key":"39406_CR22","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/CIRCRESAHA.124.325212","volume":"135","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. CAR-Macrophage therapy alleviates myocardial Ischemia-Reperfusion injury. Circul. Res. 135, 1161\u20131174 (2024).","journal-title":"Circul. Res."},{"key":"39406_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini, S. et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2\u2009+\u2009solid tumors to PD1 Blockade in pre-clinical models. Nat. Commun. 16, 706 (2025).","journal-title":"Nat. Commun."},{"key":"39406_CR24","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss, K. A. et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat. Med. 31, 1171\u20131182 (2025).","journal-title":"Nat. Med."},{"key":"39406_CR25","doi-asserted-by":"publisher","first-page":"1464218","DOI":"10.3389\/fcell.2024.1464218","volume":"12","author":"T Huang","year":"2024","unstructured":"Huang, T., Bei, C., Hu, Z. & Li, Y. CAR-macrophage: breaking new ground in cellular immunotherapy. Front. Cell. Dev. Biol. 12, 1464218 (2024).","journal-title":"Front. Cell. Dev. Biol."},{"key":"39406_CR26","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.3390\/cells11223692","volume":"11","author":"M Liu","year":"2022","unstructured":"Liu, M. et al. CAR-Macrophages and CAR-T cells synergistically kill tumor cells in vitro. Cells 11, 3692 (2022).","journal-title":"Cells"},{"key":"39406_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","volume":"11","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo, K., Taremi, S., Heidari, M. & Esmaeilzadeh, A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomark. Res. 11, 103 (2023).","journal-title":"Biomark. Res."},{"key":"39406_CR28","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"DJ Kloosterman","year":"2023","unstructured":"Kloosterman, D. J. & Akkari, L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell 186, 1627\u20131651 (2023).","journal-title":"Cell"},{"key":"39406_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan, Z. & Luo, Y. Targeting macrophages in cancer immunotherapy. Signal. Transduct. Target. Ther. 6, 127 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"39406_CR30","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s00262-023-03490-8","volume":"72","author":"Z Duan","year":"2023","unstructured":"Duan, Z., Li, Z., Wang, Z., Chen, C. & Luo, Y. Chimeric antigen receptor macrophages activated through TLR4 or IFN-\u03b3 receptors suppress breast cancer growth by targeting VEGFR2. Cancer Immunol. Immunother. 72, 3243\u20133257 (2023).","journal-title":"Cancer Immunol. Immunother"},{"key":"39406_CR31","doi-asserted-by":"publisher","first-page":"100256","DOI":"10.1016\/j.jbc.2021.100256","volume":"296","author":"S Walbaum","year":"2021","unstructured":"Walbaum, S. et al. Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms. J. Biol. Chem. 296, 100256 (2021).","journal-title":"J. Biol. Chem."},{"key":"39406_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.0022-202X.2004.23459.x","volume":"125","author":"JE McInturff","year":"2005","unstructured":"McInturff, J. E., Modlin, R. L. & Kim, J. The role of Toll-like receptors in the pathogenesis and treatment of dermatological disease. J. Invest. Dermatology. 125, 1\u20138 (2005).","journal-title":"J. Invest. Dermatology"},{"key":"39406_CR33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s43440-024-00613-5","volume":"76","author":"V Sharma","year":"2024","unstructured":"Sharma, V., Sharma, P. & Singh, T. G. Mechanistic insights on TLR-4 mediated inflammatory pathway in neurodegenerative diseases. Pharmacol. Rep. 76, 679\u2013692 (2024).","journal-title":"Pharmacol. Rep."},{"key":"39406_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1146\/annurev.iy.06.040188.003213","volume":"6","author":"H Clevers","year":"1988","unstructured":"Clevers, H., Alarcon, B., Wileman, T. & Terhorst, C. The T cell receptor\/CD3 complex: a dynamic protein ensemble. Annu. Rev. Immunol. 6, 629\u2013662 (1988).","journal-title":"Annu. Rev. Immunol."},{"key":"39406_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 Spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"39406_CR36","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.4049\/jimmunol.1700069","volume":"199","author":"ML Bettini","year":"2017","unstructured":"Bettini, M. L. et al. Cutting edge: CD3 ITAM diversity is required for optimal TCR signaling and thymocyte development. J. Immunol. 199, 1555\u20131560 (2017).","journal-title":"J. Immunol."},{"key":"39406_CR37","doi-asserted-by":"crossref","unstructured":"Anania, J. C., Chenoweth, A. M., Wines, B. D. & Hogarth, P. M. The human Fc\u03b3RII (CD32) family of leukocyte FcR in health and disease. Front Immunol 10, (2019).","DOI":"10.3389\/fimmu.2019.00464"},{"key":"39406_CR38","doi-asserted-by":"publisher","first-page":"e0279037","DOI":"10.1371\/journal.pone.0279037","volume":"18","author":"E Hickman","year":"2023","unstructured":"Hickman, E. et al. Expanded characterization of in vitro polarized M0, M1, and M2 human monocyte-derived macrophages: bioenergetic and secreted mediator profiles. PLOS ONE. 18, e0279037 (2023).","journal-title":"PLOS ONE"},{"key":"39406_CR39","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3390\/ijms25031860","volume":"25","author":"SK Suleimanov","year":"2024","unstructured":"Suleimanov, S. K. et al. Radical-Generating Activity, Phagocytosis, and mechanical properties of four phenotypes of human macrophages. Int. J. Mol. Sci. 25, 1860 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"39406_CR40","doi-asserted-by":"crossref","unstructured":"Affandi, A. J. et al. CD169 defines activated CD14\u2009+\u2009Monocytes with enhanced CD8\u2009+\u2009T cell activation capacity. Front Immunol 12, (2021).","DOI":"10.3389\/fimmu.2021.697840"},{"key":"39406_CR41","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","volume":"26","author":"P Brossart","year":"2020","unstructured":"Brossart, P. The role of antigen spreading in the efficacy of immunotherapies. Clin. Cancer Res. 26, 4442\u20134447 (2020).","journal-title":"Clin. Cancer Res."},{"key":"39406_CR42","doi-asserted-by":"publisher","first-page":"djw261","DOI":"10.1093\/jnci\/djw261","volume":"109","author":"JL Gulley","year":"2017","unstructured":"Gulley, J. L. et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. JNCI: J. Natl. Cancer Inst. 109, djw261 (2017).","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"39406_CR43","doi-asserted-by":"publisher","first-page":"1291619","DOI":"10.3389\/fimmu.2023.1291619","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang, Y., Xu, Q. & Gao, Q. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils. Front. Immunol. 14, 1291619 (2023).","journal-title":"Front. Immunol."},{"key":"39406_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu, J. et al. CAR macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomark. Res. 12, 86 (2024).","journal-title":"Biomark. Res."},{"key":"39406_CR45","doi-asserted-by":"publisher","first-page":"100098","DOI":"10.1016\/j.adcanc.2023.100098","volume":"7","author":"S Saha","year":"2023","unstructured":"Saha, S. et al. High expression of mesothelin in plasma and tissue is associated with poor prognosis and promotes invasion and metastasis in gastric cancer. Adv. Cancer Biology - Metastasis. 7, 100098 (2023).","journal-title":"Adv. Cancer Biology - Metastasis"},{"key":"39406_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40364-019-0169-8","volume":"7","author":"J Lv","year":"2019","unstructured":"Lv, J. & Li, P. Mesothelin as a biomarker for targeted therapy. Biomark. Res. 7, 18 (2019).","journal-title":"Biomark. Res."},{"key":"39406_CR47","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/cancers14061550","volume":"14","author":"JR Faust","year":"2022","unstructured":"Faust, J. R., Hamill, D., Kolb, E. A., Gopalakrishnapillai, A. & Barwe, S. P. Mesothelin: an immunotherapeutic target beyond solid tumors. Cancers 14, 1550 (2022).","journal-title":"Cancers"},{"key":"39406_CR48","doi-asserted-by":"publisher","unstructured":"Chung, J. Y. et al. Rapid CAR Screening and circRNA-driven CAR-NK Cells for Persistent Shed-resistant Immunotherapy. 08.19.671003 Preprint at (2025). https:\/\/doi.org\/10.1101\/2025.08.19.671003 (2025).","DOI":"10.1101\/2025.08.19.671003"},{"key":"39406_CR49","doi-asserted-by":"crossref","unstructured":"Chowdhury, P. S., Viner, J. L., Beers, R. & Pastan, I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proceedings of the National Academy of Sciences 95, 669\u2013674 (1998).","DOI":"10.1073\/pnas.95.2.669"},{"key":"39406_CR50","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/9872","volume":"17","author":"PS Chowdhury","year":"1999","unstructured":"Chowdhury, P. S. & Pastan, I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 17, 568\u2013572 (1999).","journal-title":"Nat. Biotechnol."},{"key":"39406_CR51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4049\/jimmunol.175.1.469","volume":"175","author":"M Lucas","year":"2005","unstructured":"Lucas, M., Zhang, X., Prasanna, V. & Mosser, D. M. ERK activation following macrophage Fc\u03b3R ligation leads to chromatin modifications at the IL-10 Locus1. J. Immunol. 175, 469\u2013477 (2005).","journal-title":"J. Immunol."},{"key":"39406_CR52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","volume":"13","author":"J Li","year":"2024","unstructured":"Li, J., Chen, P. & Ma, W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Experimental Hematol. Oncol. 13, 76 (2024).","journal-title":"Experimental Hematol. Oncol."},{"key":"39406_CR53","doi-asserted-by":"publisher","first-page":"1615760","DOI":"10.3389\/fimmu.2025.1615760","volume":"16","author":"A Morva","year":"2025","unstructured":"Morva, A., Arroyo, A. B., Andreeva, L. & Tapia-Abell\u00e1n, A. Luengo-Gil, G. Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review. Front. Immunol. 16, 1615760 (2025).","journal-title":"Front. Immunol."},{"key":"39406_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","volume":"21","author":"Y Huo","year":"2023","unstructured":"Huo, Y. et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J. Transl Med. 21, 225 (2023).","journal-title":"J. Transl Med."},{"key":"39406_CR55","doi-asserted-by":"publisher","first-page":"116930","DOI":"10.1016\/j.biopha.2024.116930","volume":"177","author":"W Zhang","year":"2024","unstructured":"Zhang, W. et al. Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials. Biomed. Pharmacother. 177, 116930 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"39406_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"39406_CR57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"39406_CR58","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00018-020-03656-y","volume":"78","author":"A Ciesielska","year":"2021","unstructured":"Ciesielska, A., Matyjek, M. & Kwiatkowska, K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell. Mol. Life Sci. 78, 1233\u20131261 (2021).","journal-title":"Cell. Mol. Life Sci."},{"key":"39406_CR59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41392-024-02096-5","volume":"10","author":"P Wang","year":"2025","unstructured":"Wang, P. et al. Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells. Signal. Transduct. Target. Ther. 10, 20 (2025).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"39406_CR60","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/s12885-015-1546-9","volume":"15","author":"M Genin","year":"2015","unstructured":"Genin, M., Clement, F., Fattaccioli, A., Raes, M. & Michiels, C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to Etoposide. BMC Cancer. 15, 577 (2015).","journal-title":"BMC Cancer"},{"key":"39406_CR61","doi-asserted-by":"publisher","first-page":"2401016","DOI":"10.1002\/smtd.202401016","volume":"9","author":"HN Lee","year":"2025","unstructured":"Lee, H. N. et al. Novel FRET-based immunological synapse biosensor for the prediction of chimeric antigen Receptor-T cell function. Small Methods. 9, 2401016 (2025).","journal-title":"Small Methods"},{"key":"39406_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12916-022-02383-4","volume":"20","author":"CK Kang","year":"2022","unstructured":"Kang, C. K. et al. Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection. BMC Med. 20, 181 (2022).","journal-title":"BMC Med."},{"key":"39406_CR63","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1128\/jvi.69.11.6705-6711.1995","volume":"69","author":"J He","year":"1995","unstructured":"He, J. et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69, 6705\u20136711 (1995).","journal-title":"J. Virol."},{"key":"39406_CR64","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1006\/viro.1995.1016","volume":"206","author":"RI Connor","year":"1995","unstructured":"Connor, R. I., Chen, B. K., Choe, S. & Landau, N. R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206, 935\u2013944 (1995).","journal-title":"Virology"},{"key":"39406_CR65","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/infdis\/jiab159","volume":"224","author":"CK Kang","year":"2021","unstructured":"Kang, C. K. et al. Longitudinal analysis of human memory T-Cell response according to the severity of illness up to 8 months after severe acute respiratory syndrome coronavirus 2 infection. J. Infect. Dis. 224, 39\u201348 (2021).","journal-title":"J. Infect. Dis."},{"key":"39406_CR66","doi-asserted-by":"publisher","first-page":"830433","DOI":"10.3389\/fimmu.2022.830433","volume":"13","author":"CK Kang","year":"2022","unstructured":"Kang, C. K. et al. Distinct immune response at 1 year Post-COVID-19 according to disease severity. Front. Immunol. 13, 830433 (2022).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39406-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39406-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39406-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:03:42Z","timestamp":1772705022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39406-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39406"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39406-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8175"}}